INTRODUCTION
Regulatory elements distant from the transcriptional start site are often composed of multiple binding sites for different transcription factors cooperating for full activity (see Ref. 8 for review). In the case of steroid hormone-responsive genes, the central transcription factor involved is the hormone receptor, which binds to a specific DNA sequence. This hormone-responsive 0888-8809/91 /1498-1503$03.00/0 Molecular Endocrinology Copyright © 1991 by The Endocrine Society element consists of a short palindromic sequence (see Ref. 3 for review). Synergistic activity has been demonstrated both between two adjacent palindromic receptor-binding sites (1, 7, 15, 25) and between a steroid receptor-binding site and any other transcription factor recognition sequence tested (25) (26) (27) . Thus, the final transcriptional activity of a hormone-dependent gene results from two effects: the intrinsic frans-activation mediated by the glucocorticoid receptor alone and the synergism resulting from adjacent binding of a second receptor or another transcription factor. For duplicated glucocorticoid or progesterone receptor-binding sites, increased DNA-binding affinities have been demonstrated (22, 24, 30) , a mechanism that is also found in some cases for the estrogen receptor (15, 19, 22) . Binding cooperativity apparently is not involved in the synergism of the glucocorticoid receptor with other transcription factors (20) , although one exception has been found (4) .
The requirement for a stereospecific alignment of the synergizing factors suggests direct or indirect interaction between the proteins (22, (24) (25) (26) . According to recently proposed models, functional synergism (not based on DNA-binding cooperativity) may involve the interaction of frans-activating domains of transcription factors with a common target, intermediary, or adaptor protein which transmits the regulatory signal to the transcription initiation complex (see Ref. 16 for review). Trans-activating domains of synergizing factors may touch a common adapter more efficiently than a single transcription factor (23) or synergizing transcription factors may activate different stages in the initiation of transcription (29) . Such a mechanism predicts that synergism is mediated by the regular intrinsic frans-activation mechanism of the factors involved. Alternatively, synergism may use a distinct mechanism mediated by direct or indirect interaction of the receptor with the neighboring transcription factor independent of its intrinsic frans-activation domains.
To find out whether synergism and intrinsic fransactivation act on a common target, we determined both activities for several receptor mutants. Both functions should be altered concomitantly if they are closely linked. We now show that domains mediating transactivation and synergism are overlapping, but not always identical.
RESULTS

Receptor Domains Mediating Synergism with the CACCC Box
We wanted to determine the contributions of different parts of the human glucocorticoid receptor to synergism with different transcription factors. Therefore, we cotransfected an expression plasmid coding for the human glucocorticoid receptor in its wild-type or mutant form along with a reporter plasmid into T47D cells [which lack functional glucocorticoid receptor (6) ]. The transcriptional activity of a reporter gene regulated by a receptor-binding sequence depends on several properties of the receptor: DNA binding, hormone binding, nuclear translocation, dimerization, protein stability, frans-activation, and synergistic interaction with transcription factors bound on adjacent sequences. To analyze only the synergistic function of receptor mutants, we compared the activity of a reference (control) reporter gene (pG29C*tkCAT) to that of a test reporter gene (pG29CtkCAT). The test reporter gene (pG29CtkCAT) contained a single imperfect palindromic receptor-binding site, as found in the long terminal repeat of the mouse mammary tumor virus, fused to a functional CACCC sequence originating from the rat tryptophan oxygenase gene (26) . A distance of 29 basepairs (bp) separating the two binding sites had been shown to be optimal for synergism (26) . This hormone-responsive unit was linked at position -105 to the thymidine kinase (tk) promoter, which, in turn, controlled the expression of the chloramphenicol acetyl transferase (CAT) gene ( Fig. 1) (26) . The reference (control) reporter gene (pG29C*tkCAT) contains a mutagenized CACCC (C*) replacing the wild-type sequence. The C* sequence does not bind nuclear factors, nor does it functionally synergize (26) . In addition, the glucocorticoid response element (GRE; -186 bp upstream of the transcriptional start site) does not synergize with transcription factors bound to the tk promoter (26) . Thus, transcriptional activity of this gene is due to the action of one isolated GRE and represents the intrinsic frans-activation activity of the tested receptor. CAT activities of these reporter constructs always reflected the amount of correctly initiated RNA (not shown).
DNA transfections were performed using constant amounts of reporter genes while increasing the concentration of the respective receptor expression plasmid, leading to increasing CAT activities. In this way the slope within the linear range of the curve (Fig. 3 ) achieved with the test reporter gene could be compared to the slope seen with the control reporter gene. Synergism was measured as the ratio between the two slopes. This strategy enables analysis even of those receptors that lead to only weak transcriptional stimulation and corrects for varying amounts of different mutated receptor species present within the cells. Within a wide range of expression plasmid concentrations, reporter gene activity increased linearly. Intrinsic frans-activation of wild-type and mutant receptors was determined with the control reporter gene (pG29C*tkCAT) at a constant amount of expression plasmid and agreed with the published values (13) . The characterized domains of the receptor are indicated in Fig. 2 : frans-activating domains TI and T 2 (13), the DNAbinding domain (DNA), and the hormone-binding domain (HBD) (12) .
Cotransfections of the wild-type receptor expression plasmid with reporter plasmids pG29C*tkCAT and pG29CtkCAT confirmed the synergistic effect of the CACCC sequence on steroid induction ( Fig. 3 and Table  1 ). The receptor deletion mutants can be categorized into four groups according to their synergizing properties, a prototype for each of these categories is shown in Fig. 3 . Only the wild-type receptor belongs to the first category, showing high activities in both synergism and intrinsic frans-activation. The second category (mutant 1-550) shows a high intrinsic frans-activation, as high as the wild-type receptor, but only a moderate synergistic activity. This mutant is a clear example that intrinsic frans-activation and synergism do not necessarily colocalize on the receptor. Another example of this kind is demonstrated by the third category, which shows the same moderate level of synergism as the second category, but exerts about a 10-fold reduced intrinsic frans-activation. A prototype of this category is mutant 1-515 (Fig. 3D) , which shows effects similar to those of mutants A77-262, A262-418, 418-777, and 1-488 (Table 1) . The fourth category is characterized by a very low intrinsic frans-activation (although clearly measurable compared with the nonbinding mutant 1 -468; Table 1 ) and no detectable synergism (Fig. 3B and Table 1 ; mutants 418-515 and 418-488).
In conclusion, all of the tested deletion mutants of the glucocorticoid receptor affect the synergism with a neighboring CACCC box factor. Intrinsic frans-activation is clearly impaired as well, but both functions do not change coordinately in some mutants. This is an indication that intrinsic frans-activation and synergism do not necessarily follow identical mechanistic pathways.
Domains outside the DNA-Binding Domain Contribute to Synergism
As all of the mutants tested above showing synergism still contained the DNA-binding domain, the question arises of whether this domain might be responsible for the observed synergism. Such a function may be undetectable in mutant 418-488, containing only the DNA-binding domain, since its intrinsic frans-activation is very low. To address this question, we decided to construct a chimeric protein where the DNA-binding domain of the receptor was replaced by the DNAbinding domain of the GAL4 protein (GR-GAL-GR). Similar fusion proteins have been used before to test for function of isolated domains of DNA-binding proteins (13, 18, 31) . Amino acids 1-147 of the GAL4 protein contain all of the properties necessary for dimerization (5) and specific binding to the palindromic UAS sequence, but do not lead to frans-activation (14) or cooperative binding to a duplicated binding site (10) . When only this domain is expressed in T47D cells, no effect whatsoever was detectable on any UAS-containing reporter plasmid (data not shown). When the fusion protein GR-GAL-GR was expressed, a strong intrinsic frans-activation was seen using the reporter gene UAS-C* containing a single GAL4-binding site. When the reporter UAS-C was used, harboring a UAS element adjacent to a CACCC box, a strong synergism was seen (Fig. 4) . Comparison of the slopes of the curves obtained with the control reporter (UAS-C*) and the test reporter plasmid (UAS-C) showed a 5-fold synergism of GR-GAL-GR with the neighboring CACCC factor. This observation clearly shows that domains outside the receptor DNA-binding domain contribute to funtional synergism.
DISCUSSION
Models for synergistic frans-activation have been suggested previously. They involve interaction of the transactivating domains with a protein called target, adaptor, or intermediary factor (see Ref. 16 for review), transmitting the regulatory signal to the transcriptional start site. In one model two transcription factors would simply provide a larger surface for such an interaction (23). Another model suggested that different frans-activating domains would activate different stages in the initiation of transcription and would, therefore, be able to synergize (29) . Both models are similar in predicting that synergism is conferred by the frans-activating pathway. An alternative model involves an additional protein contacting specific domains of the two synergizing factors.
To test whether synergism is mediated by the intrinsic frans-activating pathway, we tested several receptor deletions for their synergistic capacity with the CACCC box. Most of the receptor deletions affect both the synergism and the frans-activation even when regions outside the T1 and T2 domains are deleted. This confirms the notion that the glucocorticoid receptor may comprise at least four frans-activating functions (28) . The synergism and frans-activation observed with receptor mutants was not due to the receptor DNAbinding domain alone, present in all of the mutants, as the replacement of this domain with the DNA-binding Receptor DNA (pmoles) a Fold synergism is defined as the ratio between the slopes achieved with pG29CtkCAT and pG29C*tkCAT (see Fig. 3 ). NA, Not applicable. b Intrinsic frans-activation is determined with 0.1 pmol receptor expression plasmid and 1.5 pmol pG29C*tkCAT. domain of the yeast protein GAL4 results in a protein that is able to both frans-activate and synergize. We cannot rule out the possibility that the DNA-binding domain of the receptor might contribute to synergism, since the construct GR-GAL-GR is less efficient in synergizing than the wild-type receptor and since the DNA-binding domain of the receptor shows some (weak) frans-activation if tested alone. On the other hand, this difference in synergism may be due to nonoptimal conformation of the receptor in the GAL fusion protein. In addition to the colocalization of frans-activating and synergizing receptor properties, one important exception was found, deletion of the hormonebinding domain reduced the synergism with the CACCC box factor by about 3-fold, whereas the intrinsic transactivation of this receptor mutant tested in isolation is only marginally reduced (~0.8-fold). Such a finding argues for the presence of an additional factor, which may contact the hormone-binding domain and the CACCC box protein simultaneously.
In summary, the puzzling finding that every combination of the glucocorticoid receptor with other transcription factors led to a synergistic glucocorticoid in- duction (25) (26) (27) may be solved by the fact that particular combinations may synergize via specific functions of the multiple receptor domains. These functions include cooperative binding in the case of receptor/receptor synergism, the synergism mediated by several independent frans-activating receptor functions, and a synergizing property of the hormone-binding domain not using a strong frans-activating function.
MATERIALS AND METHODS
Plasmids
The constructs containing the indicator gene tk-CAT (CAT gene fused to the tk promoter) and carrying binding sites for the glucocorticoid receptor and the CACCC box have been described previously (24) . The pUAS 29 C*tkCAT and pUAS 29 CtkCAT were generated in an analogous fashion by replacing the GREs by the binding site CGGAGGACTGTCCTCCG (UAS) for the yeast GAL4 protein (10) , with the corresponding H/ndlll/Smal restriction sites at the 5' and 3' ends.
The expression vectors for wild-type human glucocorticoid receptor (pRShGR) and for the receptor mutants A77-262, I488,1 -515 (1515*), 1 -550 (I550*), and 1 -77/262-515 (GR15) were kindly provided by R. M. Evans (9, 13) . Mutant 418-777 was generated by replacing a Hini\/Hind\\\ fragment (amino acids 1-426) from pRShGR with a synthetic oligonucleotide duplex (5' -ACTCC AG-C AGCC AG ATCTG ACCTCCCCCAAA-CTCTGCCTGGTGTGCTCTGATGA-3'), thereby restoring the otherwise deleted part of the DNA-binding domain (amino acids 418-426). Mutant 1-488 was constructed by linearizing I488 with BamHl, filling in with Klenow enzyme, followed by religation, thereby inducing a frame shift in the natural sequence leading to 26 (17), thereby restoring the first 10 amino acids of GAL1-147, followed by insertion into the Bgl\\/BamH\ sites of mutant 418-777/I488. The resulting plasmid contains linker sequences, coding for 26 unrelated amino acids after amino acid 147.
The pRS GR-GAL-GR was generated by fusing the Kpn\/ Hind\\\ fragment (filled in with Klenow), containing the first 426 amino acids of human glucocorticoid receptor, into the Kpn\/ BglW sites (filled in with Klenow) of pRS GAL1 -147. In addition, the EcoRI and BamH\ linker sites of pRS GAL1-147 were cut, filled in with Klenow enzyme, and religated, leading to a frame shift and thereby restoring the whole C-terminal part (amino acids 488-777) of human glucocorticoid receptor.
Cell Culture and Transfection
T47D cells were transfected as previously described (2). All test plasmids (1.5 pmol) were cotransfected with different amounts of receptor expression vector, as indicated. Cells were seeded in charcoal-depleted medium, and 5 x 10~7 M dexamethasone was added. Endogeneous receptors did not influence the results, since T47D cells do not have functional glucocorticoid receptors (6) , and the use of antihormone together with receptor mutants lacking hormone-binding domain did not change the synergism. Cells were harvested and tested for CAT activity 40 h after transfection (11) . All transfections were performed in triplicate. The complete series of transfections was performed at least twice. Cell extracts were heat treated (10 min; 60 C) before carrying out the CAT assay. CAT assay conditions were chosen to yield converson rates between 0.5-60% of chloramphenicol and ranged from incubation of 5 ^g cell protein for 30 min to 150 ng for 16 h.
